DEA Slaps Seven Deadly Opioids into Schedule I Lockdown
Published Date: 10/15/2025
Rule
Summary
Starting October 15, 2025, the DEA is temporarily putting seven powerful new opioids into Schedule I, meaning they’re considered very dangerous with no accepted medical use. This affects anyone who makes, sells, studies, or even possesses these drugs, who will now face strict rules and penalties. The temporary ban lasts two years, giving the government time to keep people safe while deciding what’s next.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Seven Nitazenes Placed in Schedule I
Starting October 15, 2025, DEA temporarily places seven benzimidazole-opioids (ethyleneoxynitazene; methylenedioxynitazene; 5-methyl etodesnitazene; N-desethyl etonitazene; N-desethyl protonitazene; N,N-dimethylamino etonitazene; and N-pyrrolidino isotonitazene) in Schedule I through October 15, 2027 (with a possible one-year extension). Schedule I means these substances are treated as having high potential for abuse and no accepted medical use and are subject to Schedule I controls and sanctions.
Unauthorized Possession and Retail Sales Outlawed
Possessing any quantity of these seven substances in a manner not authorized by the Controlled Substances Act on or after October 15, 2025 is unlawful and may subject you to administrative, civil, and criminal sanctions; retail sales of Schedule I controlled substances to the general public are not allowed under the CSA.
Registration Required to Handle These Drugs
As of October 15, 2025, anyone who handles (manufactures, distributes, imports/exports, researches, analyzes, or possesses) these seven substances must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Persons currently handling these substances who are not registered must submit an application and may not continue to handle them unless DEA approves the registration.
Surrender or Dispose Stocks If Not Registered
If you possess any of these seven substances and do not want or cannot obtain a Schedule I registration, you must surrender all currently held quantities; you may not continue to lawfully hold them after October 15, 2025. The temporary order requires disposal or surrender of stocks by persons who will not be registered.
Immediate Security, Labeling, Inventory, and Reporting Rules
Beginning October 15, 2025, registrants handling these substances must meet Schedule I security requirements (21 CFR 1301.71-1301.93), labeling and packaging rules, take required inventories (initial inventory and biennial thereafter), maintain records, and submit reports and order forms as specified in 21 U.S.C. and 21 CFR parts (with current registrants given 30 calendar days from October 15, 2025 to comply with labeling, inventory, and recordkeeping requirements).
Manufacture Limited to DEA-Registered Quota Holders
Only DEA-registered manufacturers may lawfully manufacture these seven substances, and manufacturing is limited to quotas assigned under 21 U.S.C. 826 and 21 CFR part 1303, effective October 15, 2025. Manufacturers must comply with quota, order form, import/export, and reporting requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-19537, Fisheries of the Exclusive Economic Zone Off Alaska; Atka Mackerel in the Bering Sea Subarea and Eastern Aleutian District of the Bering Sea and Aleutian Islands Management Area
Starting October 9, 2025, fishing boats in the Bering Sea and Eastern Aleutian District have to stop catching Atka mackerel because they’ve hit their 2025 limit. This temporary closure helps protect the fish and keeps the fishing fair for everyone involved. The rule lasts until the end of 2025 and mainly affects trawl fishing vessels in the area.
Next: 2025-19554, Airworthiness Directives; Airbus Helicopters
If you own or fly an Airbus H160-B helicopter, listen up! The FAA found some broken parts in the main gearbox supports and now requires regular checks for cracks and fixes if needed. Starting October 30, 2025, you can’t install certain parts unless they meet new safety rules—so get ready to inspect, fix, and keep flying safe without breaking the bank.